Treatment of arthralgias and spondyloarthropathy associated with inflammatory bowel disease

Future Rheumatology

Volumn 2, Issue 4, 2007, Pages 423-431

  Becker, Heidemarie ^a   Gaubitz, Markus ^a   Domschke, Wolfram ^a   Kucharzik, Torsten ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Ankylosing spondylitis; Arthritis; Crohn's disease; Inflammatory bowel disease; Sacroiliitis; Spondyloarthritis; Spondyloarthropathy; Therapy; Ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ATLIZUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPYRONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETORICOXIB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MESALAZINE; METHOTREXATE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROBIOTIC AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VISILIZUMAB;

ADD ON THERAPY; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ARTHRALGIA; ARTHRITIS; BACKACHE; BONE NECROSIS; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; ENTERITIS; ENTHESITIS; GENETIC LINKAGE; GRANULOCYTOPENIA; HUMAN; LOW DRUG DOSE; NONHUMAN; OSTEOPOROSIS; PATIENT CARE; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; ULCERATIVE COLITIS;

EID: 34547859299     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.4.423     Document Type: Review

References (84)

1. De Vlam K, Miclants H, Cuvelier C, de Keyser F, Veys EM, de Vos M: Spondylarthropathy is underestimated in inflammatory bowel disease prevalence and HIA association. J. Rheumatol. 27(12), 2860-2865 (2000).
2. De Vos M: Joint involvement in inflammatory bowel disease. Aliment Pharmacol. Ther. 20(Suppl. 4), 36-42 (2004).
3. Palm O, Bernklev T, Moum B, Gran JT: Non-inflammatory Joint pain in patients with inflammatory bowel disease is prevalent and has a significant Impact on health related quality of life. J. Rheumatol. 32, 1755-1759 (2005).
4. Healy PJ, Helliwell PS: Classification of the spondylarthropathies. Curr. Opin. Rheumatol. 17, 395-399 (2005).
5. Holden W, Orchard T, Wordsworth P: Enteropathic arthritis. Rheum. Dis. Clin North Am. 513-530 (2003).
6. Salvarani C, Vlachonikolis IG, van der Heijde CM et al.: Musculosketal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J. Gastroenterol. 36(12), 1307-1313 (2001).
7. Orchard TR. Wordsworth BP, Jewell DP, Peripheral arthropathics - inflammatory bowel disease their articular distribution and natural history. Gut 42, 387-391 (1998).
8. Baeten D, de Keyser H, Mielants H, Veys EM: Ankylosing spondylitis and bowel disease. Practice Res. Clin. Rheumatol. 16(4), 537-549 (2002).
9. Palm O, Moum B, Ongie A. Gran JT: Prevalence of ankylosing spoodylitis and other spondyloarthropathics among patients with inflammatory bowel discase:.a population study (the IBSEN study). J. Rheumatol. 29, 511-515 (2002).
10. De la Rue SA, Bickston SJ: Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gasroenterol. 22, 365-369 (2006).
11. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr. Opin. Rheumatol. 18, 347-353 (2006).
12. Caprilli R, Gassull MA, Escher JC et al.: European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55(Suppl. 1), I36-I58 (2005).
13. Nash P, Mease PJ, Braun J et al.: Seronegative spondyloarthropathies: to lump or to split? Ann. Rheum. Dis. 64(Suppl. 2), 9-13 (2005).
14. Kucharzik T, Maaser C, Luegering A et al.: Recent understanding of IBD pathogenesis. implications for future therapies. Inflamm. Bowel. Dis. 12(11), 1068-1083 (2006).
15. Wollheim FA: Enteropathic arthritis: how do the joints talk with the gut? Curr. Opin. Rheumatol. 13, 305-309 (2001).
16. Hedenmalm K, Spigster O: Agranulocytosis and other blood dyscrasis associated with dipyrone (metamizole). Eur. J. Clin. Pharmacol. 58(4), 265-274 (2002).
17. Bonner GF, Fakhri A, Vennamaneni SR: A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease Inflamm. Bowel Dis. 10, 751-757 (2004).
18. Sandborn WJ, Stenson WF, Brynskov J et al.: Safety of celecoxib in padents with ulcerative colitis in remission: a randomized placebo-controlled pilot trial. Clin. Gastroenterol. Hepatol. 4(2), 203-211 (2006).
19. El Miedany Y, Youssef S, Ahmed I, El Gaafary M: The gastrointestinal safety and effect on disease activity of etoricoxib, a selective COX-2 inhibitor in inflammatory bowl disease. Am. J. Gastrointerol. 101 311-317 (2006).
20. Hanly JG, Mitchell M, MacMillan I, Mosher D, Sutton E. Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. J. Rheumatol. 27(3), 719-722 (2000).
21. Olivieri I, Barozzi I, Paula A. Enthesiopathy: clinical manifestations, imaging and treatment. Baillier Clin. Rheumatol. 12(4), 665-681 (1998).
22. Bernstein CN: Osteoporosis and other complications of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18(4), 428-434 (2002).
23. Klingenstein G, Levy RN, Kornbluth A. Shah AK, present DH: Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment. Pharmacol. Ther. 21(3), 243-249 (2005).
24. Dagfinrud H, Kvien TY, Hagen KB: Physiotherapy interventions for ankylosing spondylids. Cochrane Database Syst. Rev. 4, CD002822 (2004).
25. Zochling J, Braun J: Management and treatment of ankylosing spondylitis. , Curr. Opin. Rheumatol. 17, 418-425 (2005).
26. Clegg DO, Reda DJ, Abdegallatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathie: a Department of Veterans Affairs cooperative study. Athritis Rheum. 42(11), 2325-2329 (1999).
27. Dougados M, vam der Linden S, Leirisalo-Repo M et al.: Sulfasatine in the treatment of spondylarthropathy. A randomized, multicenter double-blind, placebo-controlled study. Arthritis Rheum. 38(5), 618-627 (1995).
28. Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalkylic and (mesalazine): an open trial. J. Rheumatol. 27(3), 723-726 (2000).
29. Thomson GT, Thomson BR, Thomson KS, Ducharme JS: Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J. Rheumatol. 27(3), 714-718 (2000).
30. Kaltwasser JP, Nash P, Gladman D et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arduitis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Athritis Rheum. 50(6), 1939-1950 (2004).
31. van Denderen JC, van der Paardt M. Nurmohamed. MT et al. Double blind, randomiscd, placebo controlled study of leflunomide in the treamma of active ankylosing spondylitis. Ann. Rheum. Dis. 164(12), 1761-1764 (2005).
32. Van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA: Efficacy and safety of mesalazine (Salofalk) is an open study of 20 patients with arkylosing spondylitis. J. Rheumatol. 30, 1558-1560 (2003).
33. Chen J, Liu C, Lin J: Methotrexate for ankylosing spoodylitis. Cochrane Database Syst. Rev. 4, CD004524 (2006).
34. Braun J, Zochling J, Baraliakos X et al.: Efficacy of sulfasalazine in patients with inflammatory back pan due to , undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann. Rheum. Dis. 65(9), 1147-1153 (2006).
35. Chen J, Liu C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst. 2, CD004800 (2005).
36. Salvarani C, Macchioni P, Olivieri I et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatol. 28(10). 2274-2282 (2001).
37. Manadan AM, James N, Block JA: New therapeutic approaches for pondyloarthritis. Curr Opin. Reumatol. 19, 259-264 (2007).
38. Baraliakos X, Listing J, Brandt J et al.: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. (3), R439-R444 (2005).
39. Brandt J, Khariouzov A, Listing J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48(6), 1667-1675 (2003).
40. Van der Heijde D, Dijkmans B, Geusens P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52, 582-591 (2005).
41. Generini S, Giacomelli R, Fedi R et al.: Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann. Rheum. Dis. 63, 1664-1669 (2004).
42. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O: The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol. Int. 25, 406-410 (2005).
43. Rispo A, Scarpa R, Di Girolamo E et al.: Infliximab in the treatment of extraintestinal manifestations of Crohn's disease. Scand J. Rheumatol. 34(5), 387-391 (2005).
44. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H: Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 356, 1821-1822 (2000)
45. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P: Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann. Rheum Dis. 62, 74-76 (2003).
46. Hanauer SB, Feagan BG, Lichtenstein GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
47. Rutgeerts P, Sandborn WJ, Feagan BG et al.: Infliximab for induction and maintetance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
48. Sands BE, Anderson FH, Bernstein CN et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004).
49. Targan SR, Hanauer SB, van Deventer SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035 (1997).
50. Colombel JF, Sandborn WJ, Rutgeerts P et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterol. 132(1), 52-65 (2007).
51. Hanauer SB, Sandborn WJ, Rutgeerts P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323-333; quiz 591 (2006).
52. Sandborn WJ, Rutgeerts P, Enns R et al.: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146(12), 829-838 (2007).
53. Sandborn WJ, Hanauer SB, Katz S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088-1094 (2001).
54. Schreiber S, Rutgeerts P, Fedorak RN et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129(3), 807-818 (2005).
55. Braun J, Pham T, Sieper J et al.: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. 62, 817-824 (2003).
56. Rudwaleit M, Listing J, Brandt J et al.: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann. Rheum. Dis. 63, 665-670 (2004).
57. Antoni CE, Kavanaugh A, Kirkham B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52(4), 1227-1236 (2005).
58. Brandt J, Khariouzov A, Listing J et al.: Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-α fusion receptor protein etanercept. J. Rheumatol. 31(3), 531-538 (2004).
59. Braun J, Brandt J, Listing J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359, 1187-1193 (2002).
60. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 44(9), 2112-2117 (2001).
61. Van der Heijde D, Kivitz A, Schiff MH et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136-2146 (2006).
62. Van Asache G, Vermeire S, Rutgeerts P: Safety issues with biological therapies for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22, 370-376 (2006).
63. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al.: Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66(7), 921-926. (2007).
64. Sands BE: Inflammatory bowel disease: past, present, and future. J. Gastroenterol. 42, 16-25 (2007).
65. Genovese MC, Becker JC, Schiff M et al.: Abstacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
66. Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R: Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut 55(7), 1059-1060 (2006).
67. Higashida J, Wun T, Schmidt S, Naquwa SM, Tuscano JM: Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-α treatment. J. Rheumatol. 32(11), 2109-2115 (2005).
68. Martin F, Chan AC: B cell immunobiology in disease: evolving concepts from the clinic. Ann. Rev. Immunol. 24, 467-496 (2006).
69. Bayry J, Lacroix-Desmazzes S, Kazatchkine MD, Hermine O, Tough DF, Kaveri SV: Modulation of dendritic cell maturation and function by B lymphocytes. J. Immunol. 175(1), 15-20 (2005).
70. Monteleone G, Fina D, Caruso R, Palone F: New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol. 22, 361-364 (2006).
71. Baumgart DC, Hommes DW, Reinisch W et al.: The Phase I/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with i.v. steroids (IVSR-UC): Gut 54, A57 (2005).
72. Utser TO, Auger JA, Peace D et al.: Modified anti-CD3 therapy in psoriatic arthritis: a Phase I/II clinical trial. J. Rheumatol. 29(9), 1907-1913 (2002).
73. Creed TJ, Probert CS, Norman M et al.: Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment. Pharmacol. Ther. 23(10), 1435-1442 (2006).
74. Mannon PJ, Fuss IJ, Mayer L et al.: Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004).
75. Ito H: Treatment of Crohn's disease with anti-IL-6 receptor antibody. J. Gastroenterol. 40(Suppl. 16), 32-34 (2005).
76. Maini RN, Taylor PC, Szechinski J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817-2829 (2006).
77. Nishimoto N, Yoshizaki K, Miyasaka N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
78. Gordon FH, Lai CW, Hamilton MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121(2), 268-274 (2001).
79. Gosh S, Goldin E, Gordon FH et al.: Natalizumab for active Crohn's disease. N. Engl. J. Med. 348(1), 24-32 (2003).
80. Sandborn WJ, Colombel JF, Enns R et al.: Natalizumab induction and maintenance therapy for Crohn's disease, N. Engl. J. Med. 53(18), 1912-1925 (2005).
81. Targan SR, Feagan BG, Fedorak RN et al.: Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132(5), 1672-1683 (2007).
82. MacDonald JK, McDonald JWD: Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 1, CD006097 (2007).
83. Danese S, Sans M, Spencer D et al.: Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 56(6), 855-862 (2007).
84. Karimi O, Pena AS, van Bodegraven AA: Probiotics (VSL3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc.) 41(7), 453-459 (2005).